Document:

Exhibit 10.12

 Exhibit 10.12 

[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

AMENDMENT No. 3 
 TO
THE COOPERATION AGREEMENT 
 By and between 
 Pierre et
Marie Curie University (Paris 6) 
 a French public, scientific, cultural and professional establishment 

SIRET No.: 19751722000012 - APE Code: 8452Z 
 4 Place Jussieu,
75252 Paris Cedex 05 
 Represented by its President, Mr. Jean CHAMBAZ 

Hereinafter “UPMC” 

And 
 The Centre National de la
Recherche Scientifique, (National Center for Scientific Research) 
 A French public scientific and technical research establishment, 

SIRET No. 180089013, APE Code: 7312Z 
 located at 3-5 rue
Michel Ange, 75794 PARIS CEDEX 16, 
 represented by its Director General, Mr. Alain FUCHS, 

Hereinafter referred to as “the CNRS” 

And 
 Institut National de la Santé
et de la Recherche Médicale (French National Institute of Health and Medical Research), 
 A French public, scientific and technical research
establishment, located at 101 rue de Tolbiac, 75013 PARIS 
 represented by Mr. Yves Levy, Chairman and Chief Executive Officer 

Hereinafter referred to as “INSERM” 

UPMC, the CNRS and INSERM acting both in their own name and in the name and on behalf of the Research Center Institut de la Vision (Vision Institute),
a joint research unit (UM 80) (UMRS 968 INSERM UPMC- UMR 7210 CNRS UPMC), directed by Professor José SAHEL. 
 UPMC has been authorized by the CNRS
and INSERM to sign this Cooperation Agreement in its name and on its behalf. 

 UPMC, the CNRS and INSERM being hereinafter jointly referred to as “the ESTABLISHMENTS”. 

Party of the first part 
 AND 

GENSIGHT Biologics, a French Société Anonyme, having its registered office at 74 rue du Faubourg Saint Antoine, 75012 PARIS 

Represented by Bernard GILLY, Chairman and CEO, 

Hereinafter the “Company” 

Party of the second part 
 The Establishments and
the Company are hereinafter individually referred to as a “Party” and collectively as the “Parties”. 

RECITALS: 
 The Company and UPMC, acting on behalf of the
ESTABLISHMENTS, signed, on 19 December 2013, a certain cooperation agreement (hereinafter the “Cooperation Agreement”) allowing for the creation of a priority cooperation by and between GENSIGHT and Institut de la Vision for
the performance of research work in the area of the targeting of mitochondria and treatment by gene therapy of Leber’s optic neuropathy as well as the vision restoration strategy using optogenetics in patients suffering from retinitus
pigmentosa or AMD. 
 The Cooperation Agreement has already been amended by way of two amended agreements (hereinafter the “Amended Agreements”)
signed on 20 March 2014 (Ref. UPMC C14/0665A01) and on 4 December 2014 (Ref. UPMC: C14/0665A02) respectively. 
 Taking into account the specific
agreements executed under the Cooperation Agreement and the related terms, the Parties wish to extend the term of the Cooperation Agreement by way of a third Amendment (hereinafter “3rd Amendment”). Also, the Parties wish to redefine the
financial contribution provided for in the Cooperation Agreement. 
 NOW THEREFORE, IT HAS BEEN AGREED AS FOLLOWS: 

Article I - Purpose of the 3rd Amendment 

The purpose of the 3rd Amendment is as follows: 

 

	 	•	 	extending the term of the Cooperation Agreement; and 

  

	 	•	 	increasing the financial contribution provided by the Company to the Establishments and setting forth the terms applicable to such additional financial contribution. 

 Article II – Extension of the term of the Cooperation Agreement 

The Parties decide to extend the term of the Cooperation Agreement. 

As a consequence, notwithstanding its execution date, the 3rd Amendment shall come into effect on
1 March 2015 and shall extend the term of the Cooperation Agreement until 14 March 2018. 
 Article III – Financial terms 

 Pursuant to the 3rd Amendment, the Company agrees to pay to UPMC an additional financial contribution
equal to one million one hundred sixty-eight thousand nine hundred fifty-seven euro not including the value added tax (€1,168,957 not including VAT), plus VAT at the rate applicable at the time of its invoicing, with the total contribution thus
being increased to two million two hundred nine thousand nine hundred fifty seven euro not including the value added tax (€2,209,957 not including VAT). 

The provisions of Article 9 of the Cooperation Agreement are thus deleted and replaced by the following provisions: 

“GENSIGHT financial contribution under this Agreement and the Specific Agreements is defined as follows: 

A total amount of two million two hundred nine thousand nine hundred fifty seven euro not including the value added tax (€2,209,957 not including
VAT). 
  The said compensation, plus VAT on the then applicable rate, shall be paid according to the following timetable:

  

	 	•	 	€[**] not including the value added tax as of the execution date of the Cooperation Agreement 

  

	 	•	 	€[**] not including the value added tax at the end of the first year following the execution of the Cooperation Agreement 

 

	 	•	 	€[**] and the corresponding taxes as of the execution date of this 3rd Amendment 

  

	 	•	 	€[**] and the corresponding taxes as of [**] 

  

	 	•	 	€[**] and the corresponding taxes as of [**] 

  

	 	•	 	€[**] and the corresponding taxes as of [**] 

 in consideration for the following:

  

	 	1)	completion by the LABORATORY of the Research and Cooperation activities whose programs and budgets are defined under Specific Cooperation Agreements; 

 

	 	2)	the exclusive right to use in the Area granted to GENSIGHT and its Affiliates by the ESTABLISHMENTS as regards their fraction of the ownership rights the Common Results during the period defined in Article 7.1;

 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  Financial contributions under this Agreement shall be paid to UPMC for the account of the Laboratory and
shall be specified in each Specific Agreement executed with the ESTABLISHMENT that signed the said Specific Agreement on behalf of the LABORATORY. It is agreed that the Research Activity shall be financed by GENSIGHT in an amount corresponding to
the total costs borne by the LABORATORY, while the Cooperation Activity shall be financed at least in the amount of the additional costs borne by the LABORATORY. In any event, the addition of the cost of the Research and Cooperation Activities upon
the expiration of the agreement shall not exceed the aggregate amount of €2,209,957 not including VAT (two million two hundred nine thousand nine hundred fifty-seven euro not including the value added tax) set forth in this Agreement. 

 Should one or more specific Agreements be executed with INSERM, UPMC shall re-transfer to INSERM the amounts corresponding to each of the said
Specific Agreements. 
 Upon submission of invoices by UPMC, payments shall be made to: 

Monsieur l’Agent Comptable de l’Université Pierre et Marie Curie 

RECETTE GENERALE DES FINANCES DE PARIS 

94 RUE REAUMUR 
 75002
PARIS 
 ACCOUNT NUMBER [**] 

Payments shall be made within [**] days from the end of the month following receipt of the invoice.” 

Article IV –No amendment to the other terms of the Cooperation Agreement 

All such clauses of the Cooperation Agreement and Amended Agreements as are not amended by this 3rd
Amendment shall be unchanged and shall remain fully effective among the Parties. 
 This 3rd Amendment
forms an integral part of the Cooperation Agreement. 
 Done in Paris, on 

In two (2) original copies, 
  

			
	 Université Pierre et Marie Curie
	  	The Company
	 Jean CHAMBAZ

President
	  	 Bernard GILLY

Chairman

		
	 Signature of the LABORATORY’s Director

Professor José-Alain Sahel
	  	

 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.Exhibit 10.13

 Exhibit 10.13 
  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

SPECIFIC RESEARCH COOPERATION AGREEMENT 

BY AND BETWEEN 
 Pierre et Marie Curie University
(Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 
 Hereinafter
referred to as UPMC 
 Represented by Professor Jean CHAMBAZ, Chairman, 

And 
 Institut National de la Santé
et de la Recherche Médicale (French National Institute of Health and Medical Research), a French public, scientific and technical research establishment, located at 101 rue de Tolbiac, 75013 PARIS 

Hereinafter referred to as INSERM 
 Represented by
Mr. André SYROTA, Chairman and Chief Executive Officer 
 And 

The CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (National Center for Scientific Research), a French public scientific and technical research
establishment located at 3-5 rue Michel Ange, 75794 Paris Cedex 16 
 Hereinafter referred to as the CNRS 

Represented by its Director General, Mr. Alain FUCHS 

UPMC, the CNRS and INSERM acting both in their own name and in the name and on behalf of the Research Center Institut de la Vision (Vision
Institute), a joint research unit (UM 80) (UMRS 968 INSERM UPMC- UMR 7210 CNRS UPMC), directed by Professor José SAHEL. 
 UPMC, the CNRS and INSERM
being hereinafter jointly referred to as the ESTABLISHMENTS. 
 UPMC has been authorized by the CNRS and INSERM to sign this Cooperation Agreement in its
name and on its behalf. 
 OF THE FIRST PART, 

AND 
 GenSight Biologics, a French
Société Anonyme (Corporation), whose registered office is located at 89 rue du Faubourg Saint Antoine, 75011 Paris 
 Hereinafter
referred to as “GENSIGHT” 
 Represented by Bernard GILLY, Chairman and CEO, 

  
 1 

 ON THE SECOND PART, 

INSERM, UPMC, the CNRS and GENSIGHT are hereinafter individually referred to as a “Party” and collectively as the “Parties”.

 RECITALS: 
 GENSIGHT and UPMC, acting on behalf of
the ESTABLISHMENTS, signed on 19 December 2013, a certain cooperation agreement (hereinafter the “Cooperation Agreement”) allowing for the creation of a priority cooperation by and between GENSIGHT and Institut de la Vision for
the performance of research work in the area of the targeting of mitochondria and treatment by gene therapy of Leber’s optic neuropathy as well as the vision restoration strategy using optogenetics in patients suffering from retinitus
pigmentosa or AMD. 
 Article 2 of the said Cooperation Agreement sets forth that the research work undertaken within the said framework shall be covered by
a specific agreement (hereinafter the “Specific Agreement”) specifying the rights and obligations applicable to the Parties in terms of ownership and use, in keeping with the terms and conditions of the Cooperation Agreement, with such
Specific Agreement also detailing GENSIGHT’s financial contributions under the Cooperation Agreement, with schedules setting out the scientific program and the organization of the research, as well as the complete costs borne by the LABORATORY
on the one hand and GENSIGHT on the other hand. 
 The Parties thus entered into discussions in order to define, within the scope of a specific cooperation
agreement (hereinafter the “Specific Cooperation Agreement”) the implementing terms of the aforementioned research work. 
 NOW THEREFORE, THE
PARTIES HAVE AGREED AS FOLLOWS: 
 ARTICLE 1 - PURPOSE 

The purpose of this Specific Cooperation Agreement is to define: 
  

	 	•	 	the implementing terms of a research cooperation activity (hereinafter the “Research Cooperation Activity”) entitled “Development and evaluation of the visual stimulation goggles” whose program is
attached hereto as Schedule 1 (hereinafter the “Project”); 

  

	 	•	 	the financial terms, rights and obligations of the Parties and the rules applicable as regards the ownership and use of the results derived from the Project. 

The Specific Cooperation Agreement is subject to the Cooperation Agreement which applies fully within the scope of the Project and is attached hereto as
Schedule 3. 
 Under the Specific Cooperation Agreement, the Parties are independent contractors. No provision of the Specific Cooperation Agreement should
be construed as involving any right or obligation for the Parties outside the scope of the Specific Cooperation Agreement and the Cooperation Agreement. 

  
 2 

 ARTICLE 2 - DEPLOYED RESOURCES - ORGANISATION OF THE RESEARCH 

The deployed resources (personnel, biological material, intellectual property and identified prior knowledge, etc.) and the cost associated with the completion
of the Cooperation Activity, as defined in Article 1, are specified in the detailed Financial Schedule attached as Schedule 2 and forming an integral part of this Specific Cooperation Agreement. 

The Research covered by this Agreement shall be conducted by [**] under the supervision of Ryad BENOSMAN, the LABORATORY’s Chief Science Officer. 

As regards the Project, GENSIGHT’s scientific point of contact shall be Mr. Didier PRUNEAU and any other person appointed on an ad-hoc basis
by GENSIGHT’s management after considering the particular issue covered by this specific agreement. 
  The Cooperation Activity shall be monitored
within the scope of the Steering Committee in accordance with Article 3 of the Cooperation Agreement. 
 The LABORATORY’s Chief Science Officers shall
send to GENSIGHT intermediary reports describing the project’s progress, every six months after the execution of the Specific Cooperation Agreement, and shall submit a final report upon the Agreement’s expiration date. Highly specific
attention shall be paid to the maintenance of the laboratory logs serving to record the Project’s experiments and results. Subject to a notice period of [**] days, GENSIGHT shall be entitled to procure at its own expense the audit of such
laboratory logs, by a third party appointed in order to ascertain whether the LABORATORY and the ESTABLISHMENTS have duly complied with their contractual obligations hereunder. Such audit may only be conducted in strict compliance with the Chief
Science Officers’ professional requirements and on the premises of the LABORATORY on which the Research Cooperation Activities are conducted, for the sole purpose of ascertaining the proper completion thereof. Such audit may only be conducted
within the following time slots: from 9 a.m. to 6 p.m., from Monday to Friday. 
 Should any circumstance prevent the Chief Science Officers from pursuing
the Cooperation Activities, the ESTABLISHMENTS agree to inform GENSIGHT forthwith in writing and to propose a replacement solution within [**] days. GENSIGHT shall be granted a period of [**] days in order to approve or reject the proposed solution.
Failing an agreement between the Parties concerning a replacement solution within [**] months from the date on which the Chief Science Officers no longer discharge their duties, GENSIGHT shall be entitled to terminate this Specific Cooperation
Agreement, as a matter of law, in accordance with Article 7 below. 
 Regarding the employees of the Parties who are assigned to the Project, the Parties
agree to apply Article 4 of the Cooperation Agreement. 
 ARTICLE 3 - RESPECTIVE FINANCIAL CONTRIBUTIONS OF THE PARTIES 

3.1 Each Party agrees to deploy the resources necessary in order to complete the Project. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 3 

  3.2 The Parties agree that the Cooperation Agreement executed between GENSIGHT and UPMC provides for the
payment of a total amount of one million forty-one thousand euro excluding the value added tax (€1,041,000 excluding VAT) by GENSIGHT to the ESTABLISHMENTS (see Article 9 of the Cooperation Agreement). 

Accordingly, in consideration for the undertakings assumed by the ESTABLISHMENTS under this Specific Cooperation Agreement with a view to the completion of
the Project, there shall be deducted from the total amount allocated in the Cooperation Agreement, a total all-in amount of [**] euro excluding the value added tax (€[**] excluding VAT). The Parties agree that UPMC’s management expenses
shall be deducted from the financial revenues generated by the Specific Cooperation Agreement. The deductions made since the execution date of the Cooperation Agreement shall cover a period of [**] years as follows: 

 

	 	•	 	[**] euro (€[**]) on the execution date hereof, and 

  

	 	•	 	[**] euro (€[**]) on [**] 

 In the event of any change to the VAT rate, the rate in effect as of the date
of the invoicing shall be applicable. 
 Invoices issued under the Cooperation Agreement shall specify the amounts allocated to this Specific Agreement by
referring to this document’s technical and scientific schedule. 
 ARTICLE 4 - CONFIDENTIALITY - PUBLICATIONS - COMMUNICATIONS 

The Parties agree to apply Articles 10 and 11 of the Cooperation Agreement. 

ARTICLE 5 - OWNERSHIP OF RESULTS - PROTECTION OF THE JOINT RESULTS - OPERATING PROCEDURES IN RESPECT OF THE JOINT RESULTS 

The Parties agree to apply the provisions of Articles 5.3, 5.4, 6 and 7, as well as Schedule 3 “General Principles of Co-ownership” of the
Cooperation Agreement. 
 ARTICLE 6 - TERM 
 This
Specific Cooperation Agreement shall be effective from December 20, 2013 for a term of twenty-four (24) months. 
 Notwithstanding the above term, and
regardless of the cause of termination of the Specific Cooperation Agreement, Articles 4 and 5 hereof, referring to Articles 5.3, 5.4, 6, 7, 10, and 11 of the Cooperation Agreement shall survive the termination of this Specific Cooperation
Agreement. 
 ARTICLE 7 - TERMINATION 
  This
Specific Cooperation Agreement may be terminated by either Party if the other Party fails to perform one or more of its obligations under this Agreement and has not cured the relevant breach within one (1) month from notice thereof by registered
mail, unless the defaulting Party proves that such default is attributable to an event of force majeure. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 4 

 The Party prevented from performing its contractual obligations because of the occurrence of an event of force
majeure shall immediately inform the other Party. Should such impossibility or late performance due to an event of force majeure continue after a period of [**] months, then such other Party may terminate this Agreement at any time by way of a
written notice sent to the other Party. 
 This Specific Cooperation Agreement shall also be terminated as a matter of law in case of winding-up or
court-ordered liquidation of GENSIGHT effective from the date of the court decision ordering such liquidation, subject to the provisions of Article L.621.28 of the French Commercial Code. 

Also, the Specific Cooperation Agreement may be terminated unilaterally by GENSIGHT, in accordance with the provisions of Article 2.2.1 of the Cooperation
Agreement, in the event that the ESTABLISHMENTS fail to propose to GENSIGHT a new Chief Science Officer in respect of the Agreement. 
 The exercise of the
termination right shall not release the Parties from the duty to comply with the obligations until the effective date of the Agreement’s termination. 

In the event of early termination howsoever arising, any amounts due to UPMC shall be calculated on a pro rata basis of the Research already completed
by the LABORATORY by the Agreement’s termination date, it being understood that the amounts already paid by UPMC for the remuneration of the staff shall be reimbursed to UPMC in order to enable UPMC to comply with its obligations
vis-à-vis such staff remunerated within the scope of this Specific Cooperation Agreement. 
 ARTICLE 8 - NON-TRANSFERABILITY

 The Parties agree to apply Article 13 of the Cooperation Agreement. 

ARTICLE 9 - SCHEDULES 
 The following schedules:

  

	 	•	 	Schedule 1: Description of the Research Cooperation Activity 

  

	 	•	 	Schedule 2: Budget of the Cooperation Activity 

  

	 	•	 	Schedule 3: Cooperation Agreement signed on December 19, 2013 

 form an integral part of the Specific
Cooperation Agreement. 
 In case of conflict between the provisions of this Specific Cooperation Agreement and the provisions of the Cooperation Agreement,
the provisions of the Cooperation Agreement shall prevail. 
 In case of conflict between the provisions of this Specific Cooperation Agreement and the
provisions of Schedules 1 and 2, the provisions of the Specific Cooperation Agreement shall prevail. 
 ARTICLE 10 - JURISDICTION AND APPLICABLE LAW

 This Agreement is subject to French law. 
 The
Parties shall endeavor to amicably resolve any disputes arising from the interpretation or performance of this Agreement. 

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 5 

 Should a disagreement persist after [**] months, the PARIS courts shall have jurisdiction. 

ARTICLE 11 - MISCELLANEOUS 
 11.1 This Agreement
may not be amended unless by way of an instrument previously signed by the authorised representatives of the Parties. 
 11.2 Should any provision of this
Specific Cooperation Agreement be held invalid or unenforceable, in whole or in part, by any court of competent jurisdiction, the rest of the said provision and/or the other clauses of this Specific Cooperation Agreement shall remain fully valid and
effective. 
 11.3 The Parties represent that they are party to a currently valid insurance policy covering the financial consequences of the liability that
they may incur because of any bodily injury or tangible or intangible damage inflicted on another Party or on any third party in connection with the performance of this Specific Cooperation Agreement. The rule according to which “the State is
its own insurer” shall apply to the ESTABLISHMENTS. Accordingly, the ESTABLISHMENTS represent that their own budget shall cover any damage possibly resulting from their activity. 

Done in Paris, on 28 OCT. 2014 
 In two original copies. 

 

							
	For the UPMC	 	For GENSIGHT BIOLOGICS
				
	Signature	 	/s/ Sophie Cujet	 	Signature	 	/s/ Bernard Gilly
	Name:	 	Jean CHAMBAZ	 	Name:	 	Bernard GILLY
	Title:	 	Chairman	 	Title:	 	CEO
	Date:	 	28 OCT. 2014	 	Date:	 	25/05/2014

  

	[**]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

  
 6 

			
	SIGNATURE of the Director of Institut de la Vision
		
	Signature	 	/s/ José-Alain Sahel
	Name:	 	José-Alain SAHEL
	Title:	 	Director of the Institut de la Vision Research Center
	Date:	 	14 OCT. 2014
	
	SIGNATURE of the Chief Science Officers
		
	Signature	 	/s/ Ryad Bensosman
	Name:	 	Ryad BENSOSMAN
	Title:	 	Director of Research
	Date:	 	
		
	Signature	 	/s/ Dider Pruneau
	Name:	 	Didier PRUNEAU
	Title:	 	Scientific Director - Gensight Biologics
	Date:	 	29/09/2014

  
 7 

 SCHEDULE 1 

SCIENTIFIC AND TECHNICAL SCHEDULE 

[**] 
 [**] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. 

  
 8 

 SCHEDULE 2 

DETAILED FINANCIAL SCHEDULE / DEPLOYED RESOURCES 

[**] 
 [**] Certain information in this document has been
omitted and filed separately with the Securities and Exchange Commission. 

  
 9 

 SCHEDULE 3 

COOPERATION AGREEMENT 

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]